Kate Rawson
When it comes to finding ways to control health care costs, there’s a lot of enthusiasm in Washington these days...
The Rush to Comparative Effectiveness: FDA's Woodcock Hopes It Won't Overshadow Personalized Medicine
Comparative effectiveness research is a central theme of the Obama Administration's health reform effort. But as the debate heats up on Capitol Hill, one top FDA official, Janet Woodcock, doesn't want to lose sight of an increasingly important drug development strategy: personalized medicine.
More from Platform Technologies
More from Advanced Technologies
• By
The UK regulator wants to help companies to develop bacteriophages for the treatment of infections. Its first guidance on this topic offers advice to researchers and sets out the regulatory requirements they will need to meet.
• By
The remarks from the new CBER director suggest Prasad will not be involved in most product-specific decisions.
• By
A UK research team has used artificial intelligence to find new treatments for cancer using existing US Food and Drug Administration-approved medicines that are not normally not used for the disease.